Merck & Co’s blockbuster oncology product Keytruda (pembrolizumab), which has generated over half of the company’s total revenue in the last three years, faces key patent expirations and market rivalry from 2028. Consequently, Keytruda’s projected 2032 revenues are slated to plummet by 57% relative to 2025 performance. However, the company’s non-oncology portfolio is forecasted to […]